- Home
- GILD vs BLK Comparison
GILD vs BLK Comparison
Compare GILD & BLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- BLK
- Stock Information
- Founded
- GILD 1987
- BLK 1988
- Country
- GILD United States
- BLK United States
- Employees
- GILD N/A
- BLK N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- BLK Investment Bankers/Brokers/Service
- Sector
- GILD Health Care
- BLK Finance
- Exchange
- GILD Nasdaq
- BLK Nasdaq
- Market Cap
- GILD 129.9B
- BLK 153.9B
- IPO Year
- GILD 1992
- BLK 1999
- Fundamental
- Price
- GILD $109.11
- BLK $982.61
- Analyst Decision
- GILD Buy
- BLK Strong Buy
- Analyst Count
- GILD 25
- BLK 13
- Target Price
- GILD $110.17
- BLK $1,095.54
- AVG Volume (30 Days)
- GILD 7.8M
- BLK 570.7K
- Earning Date
- GILD 08-07-2025
- BLK 07-14-2025
- Dividend Yield
- GILD 2.93%
- BLK 2.13%
- EPS Growth
- GILD 1118.07
- BLK 4.56
- EPS
- GILD 4.73
- BLK 41.15
- Revenue
- GILD $28,735,000,000.00
- BLK $20,955,000,000.00
- Revenue This Year
- GILD $1.55
- BLK $16.03
- Revenue Next Year
- GILD $3.69
- BLK N/A
- P/E Ratio
- GILD $22.83
- BLK $23.80
- Revenue Growth
- GILD 4.68
- BLK 14.23
- 52 Week Low
- GILD $62.69
- BLK $773.74
- 52 Week High
- GILD $119.96
- BLK $1,084.22
- Technical
- Relative Strength Index (RSI)
- GILD 49.92
- BLK 56.02
- Support Level
- GILD $107.19
- BLK $965.63
- Resistance Level
- GILD $111.78
- BLK $988.27
- Average True Range (ATR)
- GILD 2.77
- BLK 12.79
- MACD
- GILD -0.44
- BLK -2.98
- Stochastic Oscillator
- GILD 33.91
- BLK 53.86
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About BLK BlackRock Inc.
BlackRock is the largest asset manager in the world, with $11.584 trillion in assets under management at the end of March 2025. Its product mix is diverse, with 53% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 8% in money market funds, and 4% in alternatives. Passive strategies account for two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.